

CRONOS AUSTRALIA DELIVERS FURTHER IMPROVEMENTS TO ITS MARKET-LEADING CANVIEW MARKETPLACE PLATFORM

HIGHLIGHTS

- The six-stage rollout of “CanView 2.0” continues, with further features now rolled out:
 - Stage One: Distribution (DELIVERED)
 - Stage Two: Pharmacy (DELIVERED)
 - Stage Three: Prescriber and Patient mobile app (PILOT PROGRAM)
 - Stage Four: Supplier
 - Stage Five: Prescriber marketplace and Patient onboarding
 - Stage Six: Patient treatment tracker
- Stages four, five and six of the rollout are expected to be completed in the coming months

Melbourne, Australia, 21 September 2022 - Cronos Australia Limited (ASX:CAU) is pleased to provide an update regarding the staged rollout of the Company’s Canview 2.0 platform.

Stage One, which provides a number of order fulfilment upgrades, process improvements and other efficiencies, was deployed internally within the Company in May this year. The distribution team continues to benefit from the upgraded platform enhancements, significantly increasing the speed and accuracy of order processing enabling rapid scalability.

Stage Two, being the upgraded pharmacy ordering platform, was successfully launched to market in September. All 3,000+ pharmacy accounts on CanView have now successfully transitioned to the new software. This well-planned cut over took place seamlessly, with no interruption to regular operations. Over the last week, the Company has received minimal support requests relating to the use of the new platform, highlighting the success of the transition and the importance of the in-depth user testing and pilot program process provided by the Company. In addition to demonstrating the new user interface and seamless ordering flow design, the process also shows that the other features are fit for purpose.

New features included on Canview 2.0 for **pharmacies** include:

- Ability to receive prescriptions and TGA approvals directly from doctors/prescribers prescribing through the CanView platform and enabling patients to order their prescription repeats directly through the platform. Some of these features will only become available with the new doctor app to be introduced soon;
- Simplified ordering process with auto-matching functionality for products and dosage forms based on TGA approvals; and
- Improved visibility of available product stock levels before products are dispensed and ordered. It is expected that this feature will be available in real time in the near future.

Following the successful rollout of the improved functionality described above, during September the Company will also offer all pharmacies a further benefit of “one touch” integration with CanView and their pharmacy dispensing software which will significantly improve efficiencies and accuracy for pharmacies ordering products on the platform resulting in greater compliance and time savings.

The Company has also now completed the **Stage Three** (doctor and patient) elements of the platform which will enter the rollout phase in early October following the completion of the current pilot program. Our national MSL team, which has recently begun recruiting Medical practitioners on to the platform, will leverage their existing relationships by meeting with clinical groups as well as individual doctors to offer CanView as the “all in one” education, prescribing and compliance tool for use in clinical settings.

There are currently nearly 800 doctors registered on the CanView platform which represents less than 3% of all GPs in Australia. The remaining circa 97% of GPs not currently registered on CanView represent an exciting opportunity for the Company to increase the number of doctors using the platform in the near term.

The new doctor and patient apps provide the following new and improved functionality:

Doctors

- Seamless integration with practice management software used by doctors/prescribers to improve and streamline relevant processes;
- Ability to generate electronic prescriptions within the CanView platform (via the PMS integrations);
- Ability to store TGA approval documents in one location and to send those approvals directly to pharmacies along with electronic prescriptions;
- Ability to view available stock levels during consultations with patients. Again, it is expected that this feature will be available in real time in the near future; and
- Increased compliance features, including TGA reporting requirements.

Patients

- Ability for patients to receive prescriptions from CanView Prescribers and order repeats from the pharmacy through the mobile app;
- Ability for patients to track and check their own orders through the CanView platform; and
- Ability for patients to receive delivery notifications through the CanView mobile app and via SMS.

Cronos Australia CEO, Rodney Cocks, said:

“We are very pleased to be delivering such a wide range of important new features to our large and growing number of CanView users. The network effect on the platform is clear which will drive further patient, prescriber and pharmacist onboarding. We are confident that the improved functionality of the CanView 2.0 platform will not only provide a superior user experience but help Cronos Australia to maintain its current market-leading position.

The CanView 2.0 platform releases are, again, the outcome from an aligned focused Board and Executive with proven execution capabilities. This builds on Cronos Australia being the first profitable ASX-listed medicinal cannabis company and the first to declare a dividend.”

**** ENDS ****

About Cronos Australia Limited (ASX : CAU)

Cronos Australia Limited is listed on the ASX (ASX: CAU).

- Cronos Australia's wholly-owned subsidiary, CDA Health Pty Ltd, operates the following businesses:
 - CanView - the Group operates a successful pharmacy, doctor and patient online portal, CanView, which distributes over 160 different product SKUs within Australia from more than 25 of the most well-known international and domestic producers
 - CDA Clinics - the Group operates a successful network of clinics on the Gold Coast, Brisbane and Sunshine Coast, in addition to nationwide telehealth services
- Cronos Australia owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes face-to-face and nationwide telehealth consultations with patients seeking access to medicinal cannabis.
- See:
 - www.cronosaustralia.com
 - www.canview.com.au
 - www.cdaclinics.com.au
 - www.burleighheadscannabis.com
 - www.cannadoc.com.au

Authorised by

Rodney Cocks, Chief Executive Officer and Executive Director

Contact**Cronos Australia Limited**

Rodney Cocks
Chief Executive Officer and Executive Director
1300 799 491
info@cronosaustralia.com

Media enquiries

Mark Hawthorne
The Civic Partnership
+61 418 999 894
mark.hawthorne@civicpartners.com.au

Forward-looking statements

This announcement may include forward-looking statements. These forward-looking statements are based on Cronos Australia's expectations and beliefs concerning future events. Forward-looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of Cronos Australia, which could cause actual results to differ materially from such statements. Cronos Australia makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.